$LENZ News

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38

Piper Sandler Downgrades LENZ Therapeutics to Neutral, Lowers Price Target to $12

LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript

LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock

LENZ Therapeutics Q1 EPS $(1.32) Misses $(1.05) Estimate, Sales $1.901M Beat $1.759M Estimate

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $48

LENZ Therapeutics Files Marketing Authorization Application Review, Approval Of VIZZ To Medicines And Healthcare products Regulatory Agency To Treat Presbyopia In Adults

President of LENZ Therapeutics Picks Up 57% More Stock

LENZ Therapeutics: Speculative But Strong Buy

The Consensus EPS Estimates For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Fell Dramatically

LENZ Therapeutics: Q4 Results Highlight A Worrying Lack Of Market Demand (Rating Downgrade)

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $26

LENZ Therapeutics, Inc. Q4 2025 Earnings Call Summary

B of A Securities Maintains Buy on LENZ Therapeutics, Lowers Price Target to $29

LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...

LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript

LENZ Therapeutics Q4 Earnings Call Highlights

LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch

LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates